KR102147802B1 - 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물 - Google Patents

신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물 Download PDF

Info

Publication number
KR102147802B1
KR102147802B1 KR1020180136107A KR20180136107A KR102147802B1 KR 102147802 B1 KR102147802 B1 KR 102147802B1 KR 1020180136107 A KR1020180136107 A KR 1020180136107A KR 20180136107 A KR20180136107 A KR 20180136107A KR 102147802 B1 KR102147802 B1 KR 102147802B1
Authority
KR
South Korea
Prior art keywords
cells
transplantation
transplant rejection
transplant
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180136107A
Other languages
English (en)
Korean (ko)
Other versions
KR20200052743A (ko
Inventor
조미라
신동윤
최종영
양철우
박성환
이선영
박민정
전주연
김세영
서현범
류재윤
조근형
Original Assignee
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020180136107A priority Critical patent/KR102147802B1/ko
Application filed by 가톨릭대학교 산학협력단 filed Critical 가톨릭대학교 산학협력단
Priority to EP19882758.6A priority patent/EP3878443A4/en
Priority to US17/290,637 priority patent/US11969397B2/en
Priority to PCT/KR2019/015055 priority patent/WO2020096371A1/ko
Priority to CN201980073598.8A priority patent/CN113194936A/zh
Priority to JP2021524277A priority patent/JP7470683B2/ja
Priority to AU2019377749A priority patent/AU2019377749B2/en
Priority to CA3118881A priority patent/CA3118881A1/en
Publication of KR20200052743A publication Critical patent/KR20200052743A/ko
Application granted granted Critical
Publication of KR102147802B1 publication Critical patent/KR102147802B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020180136107A 2018-11-07 2018-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물 Active KR102147802B1 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020180136107A KR102147802B1 (ko) 2018-11-07 2018-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
US17/290,637 US11969397B2 (en) 2018-11-07 2019-11-07 Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
PCT/KR2019/015055 WO2020096371A1 (ko) 2018-11-07 2019-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
CN201980073598.8A CN113194936A (zh) 2018-11-07 2019-11-07 含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物
EP19882758.6A EP3878443A4 (en) 2018-11-07 2019-11-07 COMPOSITION FOR THE PREVENTION AND TREATMENT OF TRANSPLANT REJECTION OR TRANSPLANT REJECTION DISEASES WITH A NOVEL COMPOUND AND A CALCINEURIN INHIBITOR
JP2021524277A JP7470683B2 (ja) 2018-11-07 2019-11-07 新規な化合物およびカルシニューリン阻害剤を含む、移植拒絶反応または移植拒絶疾患を予防および治療するための組成物
AU2019377749A AU2019377749B2 (en) 2018-11-07 2019-11-07 Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor
CA3118881A CA3118881A1 (en) 2018-11-07 2019-11-07 Composition for preventing and treating transplant rejection or transplant rejection diseases, comprising novel compound and calcineurin inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180136107A KR102147802B1 (ko) 2018-11-07 2018-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물

Publications (2)

Publication Number Publication Date
KR20200052743A KR20200052743A (ko) 2020-05-15
KR102147802B1 true KR102147802B1 (ko) 2020-08-25

Family

ID=70612506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180136107A Active KR102147802B1 (ko) 2018-11-07 2018-11-07 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물

Country Status (8)

Country Link
US (1) US11969397B2 (https=)
EP (1) EP3878443A4 (https=)
JP (1) JP7470683B2 (https=)
KR (1) KR102147802B1 (https=)
CN (1) CN113194936A (https=)
AU (1) AU2019377749B2 (https=)
CA (1) CA3118881A1 (https=)
WO (1) WO2020096371A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554139B2 (en) * 2019-05-17 2023-01-17 Tolerogenixx Gmbh MIC therapy for specific immunosuppression in transplantation
CN115843745A (zh) * 2021-09-26 2023-03-28 泰州迈博太科药业有限公司 一种人源化肠炎小鼠模型的构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015167243A1 (ko) * 2014-04-29 2015-11-05 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637038B2 (en) 2011-04-12 2014-01-28 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection
US10369121B2 (en) 2013-08-23 2019-08-06 The Catholic University Of Korea Industry-Academic Cooperation Foundation Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient
JP6462002B2 (ja) 2014-04-29 2019-01-30 ザ カトリック ユニバーシティ オブ コリア インダストリー−アカデミック コーオペレイション ファウンデーション 免疫疾患治療効果を有する新規化合物およびその使用
KR101613371B1 (ko) 2014-11-10 2016-04-18 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
KR20180038355A (ko) 2016-10-06 2018-04-16 서울과학기술대학교 산학협력단 탄성 및 기계적 물성이 우수한 탄성 고분자-세라믹 하이브리드 필름 및 이의 제조방법
KR20190045513A (ko) 2017-10-24 2019-05-03 가톨릭대학교 산학협력단 Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015167243A1 (ko) * 2014-04-29 2015-11-05 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도

Also Published As

Publication number Publication date
US20220031637A1 (en) 2022-02-03
EP3878443A4 (en) 2022-08-24
WO2020096371A1 (ko) 2020-05-14
US11969397B2 (en) 2024-04-30
JP7470683B2 (ja) 2024-04-18
EP3878443A1 (en) 2021-09-15
AU2019377749B2 (en) 2024-10-03
AU2019377749A2 (en) 2021-06-03
CN113194936A (zh) 2021-07-30
CA3118881A1 (en) 2020-05-14
KR20200052743A (ko) 2020-05-15
JP2022513590A (ja) 2022-02-09
AU2019377749A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
Gazdic et al. Crosstalk between mesenchymal stem cells and T regulatory cells is crucially important for the attenuation of acute liver injury
US11872250B2 (en) Methods for inducing an immune response by administering activated mesenchymal stem cells
Jaksch et al. The pathophysiology of acute graft‐versus‐host disease
KR101578591B1 (ko) 간엽줄기세포 및 면역조절 t 세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
EP2941257B1 (en) Disease therapy using a tolerogenic pharmaceutical preparation
US20080305079A1 (en) Myeloid Suppressor Cells, Methods For Preparing Them, and Methods For Using Them For Treating Autoimmunity
Zhang et al. Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance
WO2011021833A2 (ko) 염증 예방 또는 치료용 조성물
KR102147802B1 (ko) 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물
KR20190045513A (ko) Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물
Rother et al. Complement in inflammation: induction of nephritides and progress to chronicity
Chen et al. Neutralization of mouse interleukin-17 bioactivity inhibits corneal allograft rejection
KR101694554B1 (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
JP5815767B2 (ja) 免疫学的疾患の処置のためのチモシンα１の使用
KR101273747B1 (ko) Ｓｔａ-21을 유효성분으로 함유하는 관절염의 예방 및 치료용 조성물
US20250009817A1 (en) Immunomodulating composition containing gasseri
KR20130139576A (ko) Ｉｌ-2 및 ｉｌ-2 항체를 유효성분으로 포함하는 노화 및 노인면역질환의 예방 또는 치료용 조성물
KR101705378B1 (ko) 간엽줄기세포 및 ⅰｌ-21 차단제를 포함하는 이식편대숙주질환의 예방 또는 치료용 조성물
KR101932840B1 (ko) 용해성 ｐｄ－ｌ１이 처리된 면역조절능을 갖는 골수유래억제세포 및 이의 용도
CN103896812A (zh) N，n’－二环己基－n－高级脂肪酸酰脲类似物及其制药用途

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6